“The randomised trials [of psychiatric drugs] that have been conducted do not properly evaluate the drugs’ effects,” writes Prof. Peter Gøtzsche, MD.
“Almost all of them are biased because they included patients already taking another psychiatric drug.
“Patients, who after a short wash-out period are randomised to placebo, go “cold turkey” and often experience withdrawal symptoms.
“This design exaggerates the benefits of treatment and increases the harms in the placebo group, and it has driven patients taking placebo to suicide in trials in schizophrenia.
[This creates the illusion of adverse effects in the placebo group because people in the placebo group are experiencing drug withdrawal from being taken off of their previous psychiatric drug, which then makes the drug group look better relative to the placebo group, and the drug companies can claim that the drug group did better than placebo, and can claim there was no difference in numbers of adverse events between the two groups, which is an illusion because of the way the study was designed.]
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.